Trials / Conditions / Acute Myeloid Leukemia With FLT3/ITD Mutation

Acute Myeloid Leukemia With FLT3/ITD Mutation

15 registered clinical trials studyying Acute Myeloid Leukemia With FLT3/ITD Mutation — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants NCT07162116	Shijiazhuang Yiling Pharmaceutical Co. Ltd	Phase 1
Recruiting	SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and NCT06222580	Uma Borate	Phase 1
Not Yet Recruiting	A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutati NCT05876832	Shijiazhuang Yiling Pharmaceutical Co. Ltd	Phase 3
Unknown	The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT NCT05596981	Nanfang Hospital, Southern Medical University	—
Unknown	The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT NCT05596968	Nanfang Hospital, Southern Medical University	—
Recruiting	Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML NCT05024552	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Unknown	AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance NCT04174612	Gruppo Italiano Malattie EMatologiche dell'Adulto	Phase 3
Terminated	Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukem NCT03735875	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486	Roswell Park Cancer Institute	Phase 2
Terminated	Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mut NCT02634827	Mayo Clinic	Phase 2
Completed	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Completed	Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leuke NCT01578109	National Cancer Institute (NCI)	Phase 1
Completed	Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD NCT04788420	Nanfang Hospital, Southern Medical University	—
Completed	Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia NCT01253070	National Cancer Institute (NCI)	Phase 2
Terminated	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716	Fred Hutchinson Cancer Center	Phase 2